, Volume 191, Issue 4, pp 1023–1026

Aripiprazole in treatment of borderline patients, part II: an 18-month follow-up

  • Marius K. Nickel
  • Thomas H. Loew
  • Francisco Pedrosa Gil
Original Investigation

DOI: 10.1007/s00213-007-0740-0

Cite this article as:
Nickel, M.K., Loew, T.H. & Gil, F.P. Psychopharmacology (2007) 191: 1023. doi:10.1007/s00213-007-0740-0



Only one controlled trial is known that employed aripiprazole for patients with borderline personality disorder (BPD). This 8-week trial found significant changes on most scales of the symptom checklist (SCL-90-R), Hamilton depression rating scale (HDRS), Hamilton anxiety rating scale (HARS), and on all scales of the state–trait anger expression inventory (STAXI).

Objectives, materials, and methods

To assess the long-term effectiveness of aripiprazole with multifaceted borderline symptomology, this 18-month follow-up observation with biannual testing was carried out with the same patients from the previous trial (treated with 15-mg aripiprazole daily, n = 26, 21 female and 5 male patients; previous placebo group, n = 26, 22 female and 4 male patients).


According to the intent-to-treat principle, significant changes on all scales of the SCL-90-R, HDRS, HARS, and STAXI were observed in the aripiprazole-treated subjects after 18 months.


Aripiprazole appears to be an effective and relatively safe agent in the long-term treatment of patients with BPD.


Borderline personality disorderAripiprazoleHamilton depression rating scale

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Marius K. Nickel
    • 1
    • 2
  • Thomas H. Loew
    • 3
  • Francisco Pedrosa Gil
    • 4
  1. 1.Clinic for Psychosomatic Medicine and PsychotherapyMedical University of GrazBad AusseeAustria
  2. 2.University Clinic for Psychiatry 1, PMUSalzburgAustria
  3. 3.Department of Psychosomatic MedicineUniversity ClinicRegensburgGermany
  4. 4.Psychosomatic Outpatient ClinicUniversity Medicine Clinic, LMUMunichGermany